Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05575999 · ClinicalTrials.gov registry record · Phase 1
Effectiveness of Bupivacaine, Ketorolac, Ketamine, vs Bupivacaine Alone in Reducing Postoperative Pocket Pain
A Phase 1 study, sponsored by Kansas City Heart Rhythm Research Foundation.
- Not yet
- Registry status
- Phase 1
- Development phase
- 200
- Enrollment target
NCT05575999 is a Phase 1 study that has not yet begun recruiting, run by Kansas City Heart Rhythm Research Foundation. The registered enrollment target is 200 participants.
The verdict
NCT05575999, a Phase 1 study, has not yet begun recruiting, sponsored by Kansas City Heart Rhythm Research Foundation.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 200 participants
- Enrollment target
Study Summary
Bupivacaine is the most widely used local anesthetic agent across majority of the Cardiac Implantable Electronic device (CIED) implant procedures in the United States. It is hypothesized that the combination of Bupivacaine-Ketorolac-Ketamine (BKK) is more effective in alleviating perioperative and postoperative pain as compared to the use of bupivacaine alone. A few studies have been done to look for the effectiveness of BKK in abdominal surgical procedures. However, no study has been done to evaluate its efficacy and effectiveness in patients undergoing CIED insertion.
Interventions
- DRUG Bupivacaine alone OR Bupivacaine-Ketorolac-Ketamine (BKK) Combination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2026-01 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05575999
The ClinicalTrials.gov registry entry for NCT05575999 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kansas City Heart Rhythm Research Foundation, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bupivacaine alone OR Bupivacaine-Ketorolac-Ketamine (BKK) Combination is the first listed.
NCT05575999 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05575999 about?
NCT05575999 is a clinical study titled "Effectiveness of Bupivacaine, Ketorolac, Ketamine, vs Bupivacaine Alone in Reducing Postoperative Pocket Pain". Bupivacaine is the most widely used local anesthetic agent across majority of the Cardiac Implantable Electronic device (CIED) implant procedures in the United States. It is hypothesized that the combination of Bupivacaine-Ketorolac-Ketamine (BKK) is more effective in alleviating perioperative and p...
What is the current status of trial NCT05575999?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 200 participants. The study started on 2026-01. Estimated completion is 2026-12.
What interventions are being tested in trial NCT05575999?
The interventions under investigation include: Bupivacaine alone OR Bupivacaine-Ketorolac-Ketamine (BKK) Combination (DRUG).
Who is sponsoring clinical trial NCT05575999?
This trial is sponsored by Kansas City Heart Rhythm Research Foundation, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.